Estrella Immunopharma, Inc.: February 2025 8-K Filing Insights & Stock Overview

Based on the provided XML section of the financial report for Estrella Immunopharma, Inc., here are the key insights and information extracted:

1. Entity Information:

• Name: Estrella Immunopharma, Inc.
• CIK Number: 0001844417
• Location: 5858 Horton Street, Suite 370, Emeryville, CA 94608
• Contact: (510) 318-9098

2. Filing Details:

• Filing Type: 8-K
• Filing Date: February 21, 2025
• SEC File Number: 001-40608
• EIN: 86-1314502

3. Stock Information:

• Common Stock:
• • Par value: $0.0001 per share
  • Ticker Symbol: ESLA (traded on NASDAQ)
• Warrants:
• • Each whole warrant is exercisable for one share of common stock.
  • Exercise Price: $11.50 per share
  • Ticker Symbol for Warrants: ESLAW (traded on NASDAQ)

4. Context and Dates:

• Reporting Context: The information is relevant as of February 21, 2025.
• Period Covered: The report covers the same date, indicating immediate or recent disclosures rather than a cumulative period.

5. Units of Measurement:

• Financial figures are reported in USD (United States Dollars).
• Shares are also referenced as a unit of measurement.

Insights:

• The company is currently listed on NASDAQ, indicating it is publicly traded.
• The presence of both common stock and warrants suggests a strategy of raising capital through different financial instruments.
• The exercise price for the warrants at $11.50 can provide insight into investor expectations regarding the company's future valuation.
• The par value of the common stock is notably low, which is common for many startups and biotech firms, reflecting a potential focus on growth rather than immediate profitability.

This information is essential for investors and analysts evaluating Estrella Immunopharma's capital structure, market positioning, and potential future performance.